Oncolytics Biotech Inc $ONCY

What the company doesAI summary of filing

Oncolytics Biotech is a clinical-stage biopharmaceutical company developing pelareorep, an intravenously delivered immunotherapeutic based on a naturally occurring reovirus that selectively replicates in RAS-mutated tumors and activates immune responses against cancer. The company is pre-revenue and has not been profitable since inception; it does not expect to generate significant revenues unless pelareorep becomes commercially viable. Pelareorep is being evaluated in clinical trials for gastrointestinal cancers, including colorectal cancer, pancreatic cancer, and anal cancer, as well as breast cancer, typically in combination with existing cancer treatments such as chemotherapy and checkpoint inhibitors. The company plans to pursue regulatory approval through the FDA and other authorities and intends to establish strategic partnerships with larger pharmaceutical companies to support future clinical development and commercialization. [10-K 2026-03-30]

Segments: Pelareorep (oncolytic reovirus immunotherapy)